Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery

Journal of Translational Medicine

Oleg Eremin⁴  Mohamed A El-Sheemy⁴  Mohammad Ilyas¹  Gerard P Cowley³  Jennifer M Eremin⁴  Viriya Kaewkangsadan²  Chandan Verma² 

[1] Academic Department of Pathology, Faculty of Medicine and Health Sciences, University of Nottingham, A Floor West Block, Queens Medical Centre, Derby Road, Nottingham NG7 2UH, UK;Division of Surgery, Faculty of Medicine and Health Sciences, University of Nottingham, E Floor West Block, Queens Medical Centre, Derby Road, Nottingham NG7 2UH, UK;Department of Pathology, PathLinks, Lincoln County Hospital, Greetwell Road, Lincoln LN2 5QY, UK;Lincoln Breast Unit, Research and Development Department, Lincoln County Hospital, Greetwell Road, Lincoln LN2 5QY, UK

关键词: NK cells;    Neoadjuvant chemotherapy;    Breast cancer;   

Others  :  1233513
DOI  :  10.1186/s12967-015-0535-8

 received in 2014-12-03, accepted in 2015-05-14,  发布年份 2015

【 摘 要 】

Background

NK cells contribute to tumour surveillance, inhibition of growth and dissemination by cytotoxicity, secretion of cytokines and interaction with immune cells. Their precise role in human breast cancer is unclear and the effect of therapy poorly studied. The purpose of our study was to characterise NK cells in women with large (≥3 cm) and locally advanced (T3–4, N1–2, M0) breast cancers (LLABCs) undergoing neoadjuvant chemotherapy (NAC) and surgery, and to ascertain their possible contribution to a pathological complete response (pCR).

Methods

Women with LLABCs (n = 25) and healthy female donors [HFDs (n = 10)] were studied. Pathological responses in the breast were assessed using established criteria. Blood samples were collected pre and post NAC and surgery. Flow cytometry and labelled monoclonal antibodies established absolute numbers (AbNs) and percentages (%) of NK cells, and expressing granzyme B/perforin and NKG2D. In vitro NK cytotoxicity was assessed and NK cells and cytokines (IL-2, INF-γ, TGF-β) documented in tumours using immunohistochemical techniques. Data was analysed by SPSS.

Results

Women with LLABCs had significantly reduced AbNs (160.00 ± 40.00 cells/µl) but not % of NK cells, compared with HFDs (NK: 266.78 ± 55.00 cells/µl; p = 0.020). NAC enhanced the AbN (p = 0.001) and % (p = 0.006) of NK cells in patients with good pathological responses. Granzyme B ⁺ /perforin ⁺cells were significantly reduced (43.41 ± 4.00%), compared with HFDs (60.26 ± 7.00%; p = 0.003). NAC increased the % in good (p = 0.006) and poor (p = 0.005) pathological responders. Pretreatment NK cytotoxicity was significantly reduced in good (37.80 ± 8.05%) and poor (22.80 ± 7.97%) responders (p = 0.001) but remained unchanged following NAC. NK-NKG2D ⁺cells were unaltered and unaffected by NAC; NKG2D expression was increased in patients with a pCR (p = 0.001). Surgery following NAC was not beneficial, except in those with a pCR. Tumour-infiltrating NK cells were infrequent but increased peritumourally (p = 0.005) showing a significant correlation (p = 0.004) between CD56 ⁺cells and grade of response. Tumour cytokines had no effect.

Conclusion

Women with LLABCs have inhibited blood innate immunity, variably reversed by NAC (especially with tumour pCRs), which returned to pretreatment levels following surgery. These and in situ tumour findings suggest a role for NK cells in NAC-induced breast pCR.

【 授权许可】

   
2015 Verma et al.

【 图 表 】

Figure1.

Figure2.

Figure3.

Figure4.

Figure5.

Figure6.

Figure7.

Figure8.

Figure1.

Figure2.

Figure3.

Figure4.

Figure5.

Figure6.

Figure7.

Figure8.

【 参考文献 】

• [1]Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M et al.. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000; 191(4):661-668.
• [2]Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T et al.. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat. 2007; 104(3):267-275.
• [3]Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011; 29:235-271.
• [4]Yang Q, Goding S, Hagenaars M, Carlos T, Albertsson P, Kuppen P et al.. Morphological appearance, content of extracellular matrix and vascular density of lung metastases predicts permissiveness to infiltration by adoptively transferred natural killer and T cells. Cancer Immunol Immunother. 2006; 55(6):699-707.
• [5]Sungur CM, Murphy WJ. Positive and negative regulation by NK cells in cancer. Crit Rev Oncog. 2014; 19(1–2):57-66.
• [6]Bernardini G, Santoni A. The pathophysiological role of chemokines in the regulation of NK cell tissue homing. Crit Rev Oncog. 2014; 19(1–2):77-90.
• [7]Roberti MP, Mordoh J, Levy EM. Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front Immunol. 2012; 3:375.
• [8]Strayer DR, Carter WA, Mayberry SD, Pequignot E, Brodsky I. Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. Cancer Res. 1984; 44(1):370-374.
• [9]Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000; 356(9244):1795-1799.
• [10]Vaquer S, Jorda J, Lopez de la Osa E, Alvarez de los Heros J, Lopez-Garcia N, Alvarez de Mon M. Clinical implications of natural killer (NK) cytotoxicity in patients with squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 1990; 36(1):90-92.
• [11]Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M et al.. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 2003; 20(5):445-451.
• [12]Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol. 2001; 96(2):574-578.
• [13]Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N et al.. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res. 2011; 17(4):678-689.
• [14]Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G et al.. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 2011; 71(21):6621-6632.
• [15]Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P et al.. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011; 71(16):5412-5422.
• [16]Eckl J, Buchner A, Prinz PU, Riesenberg R, Siegert SI, Kammerer R et al.. Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med (Berl). 2012; 90(1):55-66.
• [17]Sznurkowski JJ, Zawrocki A, Biernat W. Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma. Cancer Immunol Immunother. 2014; 63(3):297-303.
• [18]Garrido F, Cabrera T, Aptsiauri N. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer. 2010; 127(2):249-256.
• [19]Hoglund P, Brodin P. Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol. 2010; 10(10):724-734.
• [20]Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012; 12(4):239-252.
• [21]Desbois M, Rusakiewicz S, Locher C, Zitvogel L, Chaput N. Natural killer cells in non-hematopoietic malignancies. Front Immunol. 2012; 3:395.
• [22]Bonavida B. NK cell phenotypic and functional heterogeneities and molecular mechanisms of cytotoxicity. Crit Rev Oncog. 2014; 19(1–2):21-45.
• [23]Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C et al.. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009; 69(8):3563-3569.
• [24]Ferlazzo G, Moretta L. Dendritic cell editing by natural killer cells. Crit Rev Oncog. 2014; 19(1–2):67-75.
• [25]Garner WL, Minton JP, James AG, Hoffmann CC. Human breast cancer and impaired NK cell function. J Surg Oncol. 1983; 24(1):64-66.
• [26]Konjevic G, Jurisic V, Spuzic I. Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat. 2001; 66(3):255-263.
• [27]Konjevic G, Radenkovic S, Srdic T, Jurisic V, Stamatovic L, Milovic M. Association of decreased NK cell activity and IFNgamma expression with pSTAT dysregulation in breast cancer patients. J BUON. 2011; 16(2):219-226.
• [28]Eremin O, Coombs RR, Ashby J. Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. Br J Cancer. 1981; 44(2):166-176.
• [29]Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008; 8(1):59-73.
• [30]Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother. 2009; 58(3):317-324.
• [31]Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002; 87(1):21-27.
• [32]Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010; 102(1):115-123.
• [33]Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol. 2004; 25(2):487-491.
• [34]Walker LG, Eremin JM, Aloysius MM, Vassanasiri W, Walker MB, El-Sheemy M et al.. Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer. 2011; 11:179. BioMed Central Full Text
• [35]Brittenden J, Heys SD, Ross J, Park KG, Eremin O. Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of l-arginine supplementation. Eur J Surg Oncol. 1994; 20(4):467-472.
• [36]Khan AL, Richardson S, Drew J, Larsen F, Campbell M, Heys SD et al.. Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy. Surgery. 1995; 118(3):531-538.
• [37]Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M et al.. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010; 28(1):105-113.
• [38]Murta EF, de Andrade JM, Falcao RP, Bighetti S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori. 2000; 86(5):403-407.
• [39]Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E et al.. A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res. 2011; 13(6):R117. BioMed Central Full Text
• [40]Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G et al.. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother. 2004; 53(12):1146-1152.
• [41]Mamessier E, Pradel LC, Thibult ML, Drevet C, Zouine A, Jacquemier J et al.. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol. 2013; 190(5):2424-2436.
• [42]Beitsch P, Lotzova E, Hortobagyi G, Pollock R. Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery. Surg Oncol. 1994; 3(4):211-219.
• [43]Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M et al.. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012; 19(5):1508-1516.
• [44]von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al.. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30(15):1796-1804.
• [45]Eremin J, Cowley G, Walker LG, Murray E, Stovickova M, Eremin O. Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival. Springerplus Oncol. 2015; 4:9.
• [46]Eremin O, Ashby J, Stephens JP. Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease. Int J Cancer. 1978; 21(1):35-41.
• [47]Mackay IR, Goodyear MD, Riglar C, Penschow J. Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer. Cancer Immunol Immunother. 1983; 16(2):98-100.
• [48]Cunningham-Rundles S, Filippa DA, Braun DW, Antonelli P, Ashikari H. Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. J Natl Cancer Inst. 1981; 67(3):585-590.
• [49]White D, Jones DB, Cooke T, Kirkham N. Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease. Br J Cancer. 1982; 46(4):611-616.
• [50]Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N et al.. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother. 2009; 63(9):703-706.
• [51]Konjevic G, Jurisic V, Jovic V, Vuletic A, Mirjacic Martinovic K, Radenkovic S et al.. Investigation of NK cell function and their modulation in different malignancies. Immunol Res. 2012; 52(1–2):139-156.
• [52]Standish LJ, Sweet ES, Novack J, Wenner CA, Bridge C, Nelson A et al.. Breast cancer and the immune system. J Soc Integr Oncol. 2008; 6(4):158-168.
• [53]Tichatschek E, Zielinski CC, Muller C, Sevelda P, Kubista E, Czerwenka K et al.. Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer. Cancer Immunol Immunother. 1988; 27(3):278-282.
• [54]Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother. 2000; 49(4–5):181-185.
• [55]Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010; 17(4):616-623.
• [56]Ewen CL, Kane KP, Bleackley RC. A quarter century of granzymes. Cell Death Differ. 2012; 19(1):28-35.
• [57]Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA. Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol. 2012; 33(8):406-412.
• [58]Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E et al.. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity. 2007; 26(3):311-321.
• [59]Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C et al.. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009; 31(1):84-98.
• [60]Zhou L, Wang H, Zhong X, Jin Y, Mi QS, Sharma A et al.. The IL-10 and IFN-gamma pathways are essential to the potent immunosuppressive activity of cultured CD8+ NKT-like cells. Genome Biol. 2008; 9(7):R119. BioMed Central Full Text
• [61]Hodge G, Hodge S, Li-Liew C, Reynolds PN, Holmes M. Increased natural killer T-like cells are a major source of pro-inflammatory cytokines and granzymes in lung transplant recipients. Respirology. 2012; 17(1):155-163.
• [62]Piroozmand A, Hassan ZM. Evaluation of natural killer cell activity in pre and post treated breast cancer patients. J Cancer Res Ther. 2010; 6(4):478-481.
• [63]Obeidy P, Sharland AF. NKG2D and its ligands. Int J Biochem Cell Biol. 2009; 41(12):2364-2367.
• [64]Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I et al.. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer. 2009; 124(7):1594-1604.
• [65]Zafirova B, Wensveen FM, Gulin M, Polic B. Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci. 2011; 68(21):3519-3529.
• [66]Zhang J, Basher F, Wu JD. NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol. 2015; 6:97.
• [67]Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003; 3(10):781-790.
• [68]Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000; 1(2):119-126.
• [69]Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med. 2005; 202(5):583-588.
• [70]Marcais A, Viel S, Grau M, Henry T, Marvel J, Walzer T. Regulation of mouse NK cell development and function by cytokines. Front Immunol. 2013; 4:450.
• [71]Song H, Hur DY, Kim KE, Park H, Kim T, Kim CW et al.. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Cell Immunol. 2006; 242(1):39-45.
• [72]Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R et al.. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002; 62(21):6178-6186.
• [73]de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA et al.. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer. 2012; 12:24. BioMed Central Full Text
• [74]Verma C, Eremin JM, Robins A, Bennett AJ, Cowley GP, El-Sheemy MA et al.. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med. 2013; 11:16. BioMed Central Full Text
• [75]Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol. 2001; 19:291-330.
• [76]Trowsdale J, Parham P. Mini-review: defense strategies and immunity-related genes. Eur J Immunol. 2004; 34(1):7-17.
• [77]Watzl C, Long EO. Natural killer cell inhibitory receptors block actin cytoskeleton-dependent recruitment of 2B4 (CD244) to lipid rafts. J Exp Med. 2003; 197(1):77-85.
• [78]Hanaoka N, Jabri B, Dai Z, Ciszewski C, Stevens AM, Yee C et al.. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol. 2010; 185(10):5732-5742.
• [79]Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR et al.. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest. 2013; 123(10):4410-4422.
• [80]Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF et al.. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun. 2007; 7:17.
• [81]Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A et al.. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 2012; 72(6):1407-1415.
• [82]Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell functions. Cancer Res. 2012; 72(20):5428-5429.
• [83]Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE et al.. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol. 2005; 6(9):928-937.
• [84]Fruci D, Lo Monaco E, Cifaldi L, Locatelli F, Tremante E, Benevolo M et al.. T and NK cells: two sides of tumor immunoevasion. J Transl Med. 2013; 11(1):30. BioMed Central Full Text
• [85]Aloysius MM, Walker LG, Eremin O. Cancer and the immune response. In: Essential immunology for surgeons. Eremin O, Sewell H, editors. Oxford OUP, Oxford; 2011: p.236-300.